Zobrazeno 1 - 10
of 47
pro vyhledávání: '"CHENGXIN DENG"'
Autor:
Chao Li, ChengXin Deng, Ping Wu, KaiFan Liu, Xin Huang, MingMin Li, XiaoMei Chen, SuXia Geng, PeiLong Lai, JianYu Weng, Xin Du
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 1, Pp n/a-n/a (2024)
Abstract Chronic myelomonocytic leukemia (CMML) treatment remains a pressing clinical challenge. We conducted a retrospective analysis on 52 CMML cases, exploring the effectiveness of combining venetoclax (Vene) with hypomethylating agents (HMAs). Th
Externí odkaz:
https://doaj.org/article/438382a7e4c54e7a90df59af1f69a39b
Autor:
Xiaomei Chen, Chao Li, Yulian Wang, Suxia Geng, Maozhi Xiao, Lingji Zeng, Chengxin Deng, Minming Li, Xin Huang, Jianyu Weng, Xin Du, Peilong Lai
Publikováno v:
Hematology, Vol 28, Iss 1 (2023)
ABSTRACTThis study delves into the emerging role of ferroptosis in Myelodysplastic Neoplasms (MDS) and aims to identify a prognostic ferroptosis-related gene signature for MDS. Utilizing RNA-seq data and clinical information from the Gene Expression
Externí odkaz:
https://doaj.org/article/ce27c683265f4a74a24ebf72ffb89c5f
Autor:
Suxia Geng, Ruohao Xu, Xin Huang, Minming Li, Chengxin Deng, Peilong Lai, Yulian Wang, Ping Wu, Xiaomei Chen, Jianyu Weng, Xin Du
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Hypomethylating agents (HMAs) are widely used in patients with higher-risk MDS not eligible for stem cell transplantation. However, the general response rate by HMAs is lesser than 50% in MDS patients, while the relapse rate is high. Emerging evidenc
Externí odkaz:
https://doaj.org/article/c4f90879820d4bb0a080d4069b6b6fc0
Publikováno v:
BMC Gastroenterology, Vol 20, Iss 1, Pp 1-4 (2020)
Abstract Background Hypereosinophilic syndrome (HES) is a very rare disease and usually treated with corticosteroids. Gastrointestinal (GI) cytomegalovirus (CMV) infection is also rare but frequent in patients with immunocompromised status. These two
Externí odkaz:
https://doaj.org/article/8e93960f986a42aeb36a5f65499684ae
Autor:
MinMing Li, Chao Li, SuXia Geng, XiaoMei Chen, Ping Wu, ChengXin Deng, XiaoFang Chen, ZeSheng Lu, JianYu Weng, Xin Du
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
The treatment outcomes of intermediate or high-risk myelodysplastic syndrome (MDS) remain unsatisfactory. This study was designed to evaluate the safety and efficacy of human leukocyte antigen (HLA)-mismatched hematopoietic stem cell micro-transplant
Externí odkaz:
https://doaj.org/article/cad7c64864014820a7031da874ba039b
Autor:
Jianyu Weng, Peilong Lai, Le Qin, Yunxin Lai, Zhiwu Jiang, Chenwei Luo, Xin Huang, Suijing Wu, Dan Shao, Chengxin Deng, Lisi Huang, Zesheng Lu, Maohua Zhou, Lingji Zeng, Dongmei Chen, Yulian Wang, Xiaomei Chen, Suxia Geng, Weinkove Robert, Zhaoyang Tang, Chang He, Peng Li, Xin Du
Publikováno v:
Journal of Hematology & Oncology, Vol 11, Iss 1, Pp 1-12 (2018)
Abstract Background Anti-CD19 chimeric antigen receptor (CAR) T cells have shown promise in the treatment of B cell acute lymphocytic leukemia (B-ALL). However, its efficacy in B-ALL patients with extramedullary involvement is limited due to poor res
Externí odkaz:
https://doaj.org/article/b6cf64a982b24109a2cbe0bb1860ee0d
Autor:
Jianyu Weng, Peilong Lai, Le Qin, Yunxin Lai, Zhiwu Jiang, Chenwei Luo, Xin Huang, Suijing Wu, Dan Shao, Chengxin Deng, Lisi Huang, Zesheng Lu, Maohua Zhou, Lingji Zeng, Dongmei Chen, Yulian Wang, Xiaomei Chen, Suxia Geng, Robert Weinkove, Zhaoyang Tang, Chang He, Peng Li, Xin Du
Publikováno v:
Journal of Hematology & Oncology, Vol 12, Iss 1, Pp 1-1 (2019)
The original article [1] contains an error in authorship whereby author, Robert Weinkove’s name is mistakenly inverted. The configuration noted in this Correction article should be considered instead along with author’s updated affiliation.
Externí odkaz:
https://doaj.org/article/9034878cc2c64cb99192bcb426542bd2
Publikováno v:
Journal of Energy Chemistry. 80:228-236
Autor:
NINGYU LI, XIAOFANG CHEN, SUXIA GENG, PEILONG LAI, LISI HUANG, MINMING LI, XIN HUANG, CHENGXIN DENG, YULIAN WANG, JIANYU WENG, XIN DU
Publikováno v:
BIOCELL. 47:133-141
Autor:
Ruohao Xu, Suxia Geng, Lingji Zeng, Chengxin Deng, Xin Huang, Minming Li, Ping Wu, Peilong Lai, Jianyu Weng, Xin Du
Hypomethylating agents (HMAs) including azacitidine (AZA) represent the only FDA-approved first-line treatments for patients with chronic myelomonocytic leukemia (CMML). However, the mechanism by which HMAs produce therapeutic responses (e.g., hemato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c489c4b13e8ecd087772ebb686f4a9c7
https://doi.org/10.21203/rs.3.rs-2475679/v1
https://doi.org/10.21203/rs.3.rs-2475679/v1